LongeveronLGVN
About: Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
Employees: 24
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
4% less capital invested
Capital invested by funds: $536K [Q2] → $512K (-$24.1K) [Q3]
4.78% less ownership
Funds ownership: 6.83% [Q2] → 2.05% (-4.78%) [Q3]
10% less funds holding
Funds holding: 21 [Q2] → 19 (-2) [Q3]
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 102 / 269 met price target | 432%upside $10 | Buy Reiterated | 4 Nov 2024 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 102 / 269 met price target | 432%upside $10 | Buy Reiterated | 4 Sept 2024 |
Maxim Group Michael Okunewitch 50% 1-year accuracy 1 / 2 met price target | 219%upside $6 | Buy Maintained | 27 Aug 2024 |
Financial journalist opinion
Based on 5 articles about LGVN published over the past 30 days
